MedsPaL
THE MEDICINES PATENTS AND LICENCES DATABASE

About MedsPaL

MedsPaL provides information on the patent and licensing status of HIV, hepatitis C, tuberculosis and other patented medicines on the World Health Organization (WHO) Model List of Essential Medicines in low- and middle-income countries. Developed by the Medicines Patent Pool (MPP), it offers an overview of the intellectual property status of priority medicines in developing countries.

Key Features of MedsPaL

- Searchable by key words, pharmaceutical products and countries
- Regularly updated through automated data feeds, online searches, patent holder disclosures and collaboration with patent experts, national/regional patent offices and international organisations (e.g. WHO, World Intellectual Property Organization)
- Patent cards with legal status, patent numbers, expected expiry dates and other patent information
- Links to patents available on Espacenet, the European Patent Office’s public database
- Licence cards with publicly-available information on relevant licences, including links to further information and to full MPP licences
- E-mail sign-up to enable regular communications with users on updates and upcoming features
- Information on regulatory data exclusivity in countries where such exclusivity is provided under national law
- Possibility to export results for further analysis

MedsPaL in Numbers

- Patent status data on more than 6,800 national patent applications
- From more than 110 low- and middle-income countries
- Covering 70 priority medicines (130+ formulations)
- With information on 39 licences and other access agreements in low- and middle-income countries
- And data exclusivity information from 15 countries

MedsPaL is a database hosted by the Medicines Patent Pool, a United Nations-backed public health organisation working to increase access to HIV, hepatitis C and tuberculosis treatments in low- and middle-income countries through voluntary licensing and patent pooling. The organisation’s HIV, hepatitis C and TB activities are fully funded by Unitaid. Funding provided by the Swiss Agency for Development and Cooperation (SDC) for MPP’s feasibility study on the potential expansion of its licensing activities into patented essential medicines made the upgrade of MedsPaL to include other essential medicines possible.